• About WordPress
    • WordPress.org
    • Documentation
    • Learn WordPress
    • Support
    • Feedback
  • Log In
  • Request Membership
Skip to content
Medxy AI Medxy AI
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • facebook.com
  • twitter.com
  • t.me
  • instagram.com
  • youtube.com
Subscribe
  • Home
  • KEYNOTE-966
Maintaining Quality of Life While Extending Survival: HRQoL Outcomes from KEYNOTE-966 in Advanced Biliary Tract Cancer
Posted inClinical Updates news Oncology

Maintaining Quality of Life While Extending Survival: HRQoL Outcomes from KEYNOTE-966 in Advanced Biliary Tract Cancer

Posted by By MedXY 09/20/2025
The KEYNOTE-966 trial demonstrates that adding pembrolizumab to gemcitabine and cisplatin improves overall survival in advanced biliary tract cancer patients without compromising health-related quality of life.
Read More
  • Mitochondrial Calcium Deficit Links Structural Remodeling to Atrial Fibrillation — and an Old Cholesterol Drug, Ezetimibe, Shows Unexpected Anti‑AF Potential
  • APOE ε4, Age and Sex Converge to Disturb Anterior Olfactory Nucleus Physiology: Electrophysiologic Evidence for Early Alzheimer’s Vulnerability
  • Tau Links Amyloid and Vascular Burden to Faster Clinical Decline: Chronicity Reveals Synergy Between White Matter Injury and Amyloid in Dementia Progression
  • Subclinical Vascular Burden Predicts 20‑Year Cognitive Decline: Arteriosclerosis and Atherosclerosis Outperform Blood Pressure and Cardiac Measures
  • Exceptional Efficacy of Olverembatinib in a Subtype of Gastrointestinal Stromal Tumors with Marked Improvement in Progression-Free Survival
  • About us
  • Contact us
  • MedXY story
  • Privacy Policy
  • Subscribe Now!
  • 账号
  • English
  • 日本語
  • Tiếng Việt
  • 中文

aging Alzheimer's disease artificial intelligence atrial fibrillation biomarkers blood pressure breast cancer cardiovascular disease cardiovascular health cardiovascular risk clinical trial depression diabetes diet epidemiology exercise gut microbiota health heart failure Hypertension immunotherapy inflammation knee osteoarthritis MASLD mental health metformin Mortality multiple myeloma nutrition obesity older adults Physical Activity Pregnancy prevention prognosis public health randomized clinical trial randomized controlled trial randomized trial sexual health targeted therapy treatment type 2 diabetes weight loss women's health

Your health, we care

Copyright 2025 — Medxy AI. All rights reserved.
Scroll to Top
Sign in